Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Allogeneic Stem Cell Transplantation in Patients ≥70 Years Old

Christopher C Walling, BS, Pamela A Shaw, PhD, Noelle V Frey, MD, Saar I Gill, MBBS, PhD, Elizabeth O. Hexner, MD, Alison W Loren, MD MS, Selina Luger, MD, James K Mangan, MD PhD, Mary Ellen Martin, MD, Jacqueline Smith, CRNP, Edward A. Stadtmauer, MD, David L. Porter, MD

Blood (2016) 128 (22): 2309.

https://doi.org/10.1182/blood.V128.22.2309.2309

Published: 2016

Journal Articles

Oral Vancomycin Is Highly Effective in Preventing Clostridium Difficile infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Alex Ganetsky, PharmD, BCOP, Jennifer H Han, MD MSCE, Mitchell E Hughes, PharmD, Daria V. Babushok, MD PhD, Noelle V Frey, MD, Saar I Gill, MBBS, PhD, Elizabeth Hexner, MD, Alison Wakoff Loren, MD MS, Selina Luger, MD, James K Mangan, MD PhD, Jacqueline Smith, CRNP, Edward A. Stadtmauer, MD, Craig W. Freyer, PharmD, BCOP, Cheryl Gilmar, MT, David L Porter, MD

Blood (2016) 128 (22): 2225.

https://doi.org/10.1182/blood.V128.22.2225.2225

Published: 2016

Journal Articles

Tocilizumab Is Highly Active for Severe Steroid-Refractory Acute Graft-Versus-Host Disease of the Gastrointestinal Tract

Alex Ganetsky, PharmD, BCOP, Noelle V Frey, MD, Alison W Loren, MD MS, Elizabeth O. Hexner, MD, James K Mangan, MD PhD, Saar I Gill, MBBS, PhD, Selina Luger, MD, Adam D. Cohen, MD, Daria V Babushok, MDPhD, Edward A Stadtmauer, MD, Jacqueline Smith, CRNP, William R. Drobyski, MD, Sarah K Kraus, PharmD, Colleen Timlin, PharmD, BCOP, David L. Porter, MD

Blood (2016) 128 (22): 2245.

https://doi.org/10.1182/blood.V128.22.2245.2245

Published: 2016

Journal Articles

Clofarabine Busulfan Conditioning Improves Outcomes in Patients with Active Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplant

Alexis Zebrowski, BA, Alexandra Hanlon, PhD, James Mangan, MD PhD, Jennifer Pinto-Martin, PhD MPH, Selina M. Luger, MD, Alison W. Loren, MD, Elizabeth O Hexner, MD, Ran Reshef, MD, Saar I. Gill, MD PhD, Jacqueline Smith, CRNP, Edward A. Stadtmauer, MD, David Porter, MD, Noelle V. Frey, MDMS

Blood (2014) 124 (21): 1239.

https://doi.org/10.1182/blood.V124.21.1239.1239

Published: 2014

Journal Articles

Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival

Anita J. Kumar, MDMS, Pavel Vassilev, BS, Alison W. Loren, MDMS, Selina M. Luger, MD, Ran Reshef, MD, Saar I. Gill, MD PhD, Jacqueline Smith, CRNP, Steven C. Goldstein, MD, Elizabeth Hexner, MD, Edward A. Stadtmauer, MD, David Porter, MD, Noelle V. Frey, MDMS

Blood (2014) 124 (21): 3946.

https://doi.org/10.1182/blood.V124.21.3946.3946

Published: 2014

Journal Articles

Whole Blood Donor Chimerism At Day 30 After Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation Predicts Disease Relapse, and Is Strongly Associated with Pretransplant Lymphodepletion

Ran Reshef, MD, Rosemarie Mick, MS, Pavel Vassilev, BS, Jacqueline Smith, CRNP, Elizabeth Hexner, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Steven C. Goldstein, MD, Edward A. Stadtmauer, MD, Selina M. Luger, MD, David L. Porter, MD

Blood (2011) 118 (21): 1939.

https://doi.org/10.1182/blood.V118.21.1939.1939

Published: 2011

Journal Articles

Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study

Ran Reshef, MD, Selina M. Luger, MD, Elizabeth O. Hexner, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Steven C. Goldstein, MD, Sunita D. Nasta, MD, Edward A. Stadtmauer, MD, Jacqueline Smith, CRNP, Rosemarie Mick, MS, Daniel F. Heitjan, PhD, James A. Hoxie, MD, Stephen G. Emerson, MD, PhD, Robert H. Vonderheide, MD, PhD, David L. Porter, MD

Blood (2011) 118 (21): 1011.

https://doi.org/10.1182/blood.V118.21.1011.1011

Published: 2011

Journal Articles

Prevention of Graft-Versus-Host Disease by Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist

Ran Reshef, MD, Selina M. Luger, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Steven C. Goldstein, MD, Elizabeth O. Hexner, MD, Edward A. Stadtmauer, MD, Jacqueline Smith, CRNP, Rosemarie Mick, MS, Daniel F. Heitjan, PhD, Susan E. Shetzline, PhD, Gwenn-ael H. Danet-Desnoyers, PhD, Stephen G. Emerson, MD, PhD, James A. Hoxie, MD, Robert H. Vonderheide, MD, PhD, David L. Porter, MD

Blood (2010) 116 (21): 673.

https://doi.org/10.1182/blood.V116.21.673.673

Published: 2010

Journal Articles

Reduced Intensity Conditioning with Fludarabine/Busulfan 6.4mg/Kg Results In High Donor Chimerism and Low Toxicity In Both Related and Unrelated Allo-SCT for Hematologic Malignancies.

Steven C Goldstein, MD, Selina M. Luger, MD, Noelle Frey, MD, Alexander Perl, MD, Edward A Stadtmauer, MD, Donald Tsai, MD, Alison Loren, MD, Sunita Nasta, MD, Elizabeth Hexner, MD, Ran Reshef, MD, Jacqueline Smith, CRNP, Joanne Hinkle, Pavel Vassilev, BS, Michael J Vozniak, PharmD, David L. Porter, MD

Blood (2010) 116 (21): 4519.

https://doi.org/10.1182/blood.V116.21.4519.4519

Published: 2010

NARROW

Allogeneic Stem Cell Transplantation in Patients ≥70 Years Old

Oral Vancomycin Is Highly Effective in Preventing Clostridium Difficile infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Tocilizumab Is Highly Active for Severe Steroid-Refractory Acute Graft-Versus-Host Disease of the Gastrointestinal Tract

Clofarabine Busulfan Conditioning Improves Outcomes in Patients with Active Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplant

Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival

Whole Blood Donor Chimerism At Day 30 After Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation Predicts Disease Relapse, and Is Strongly Associated with Pretransplant Lymphodepletion

Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study

Prevention of Graft-Versus-Host Disease by Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist

Reduced Intensity Conditioning with Fludarabine/Busulfan 6.4mg/Kg Results In High Donor Chimerism and Low Toxicity In Both Related and Unrelated Allo-SCT for Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only